Katja Rothfuss

Dr. Katja Rothfuss

Robert Bosch Hospital, Stuttgart, Baden-Württemberg, Germany
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in World Journal of Gastroenterology
Verified
Journal Article
Open access
KRKatja Rothfuss
Katja Rothfuss
ESEduard F Stange
Eduard F Stange
KHKlaus R Herrlinger
Klaus R Herrlinger
Extraintestinal manifestations and complications in inflammatory bowel diseases

11 October 2019 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
EEElena Eliadou
Elena Eliadou
JMJoana Moleiro
Joana Moleiro
Davide Giuseppe RibaldoneDavide Giuseppe Ribaldone
Davide Giuseppe Ribaldone
MAMarco Astegiano
Marco Astegiano
KRKatja Rothfuss
Katja Rothfuss
ECECCO CONFER COMMITTEE
ECCO CONFER COMMITTEE
Background: Interstitial lung [ILD] disease and granulomatous lung disease [GLD] are rare respiratory disorders that have been associated with inflammatory bowel disease [IBD]. Clinical presentation is polymorphic and aetiology is unclear.Methods: This was an ECCO-CONFER project. Cases of concomitant ILD or GLD and IBD, or drug-induced ILD/GLD, were collected. The criteria for diagnosing ILD and GLD were based on definitions from the American Thoracic Society and the European Respiratory Society and on the discretion of reporting clinician.Results: We identified 31 patients with ILD. The majority had ulcerative colitis [UC] [n = 22]. Drug-related ILD was found in 64% of these patients, 25 patients [80.6%] required hospitalisation, and one required non-invasive ventilation. The causative drug was stopped in all drug-related ILD, and 87% of patients received systemic steroids. At follow-up, 16% of patients had no respiratory symptoms, 16% had partial improvement, 55% had ongoing symptoms, and there were no data in 13%. One patient was referred for lung transplantation, and one death from lung fibrosis was reported. We also identified 22 GLD patients: most had Crohn’s disease [CD] [n = 17]. Drug-related GLD was found in 36% of patients and 10 patients [45.4%] required hospitalisation. The causative drug was stopped in all drug-related GLD, and 81% of patients received systemic steroids. Remission of both conditions was achieved in almost all patients.Conclusions: ILD and GLD, although rare, can cause significant morbidity. In our series, over half of cases were drug-related and therefore focused pharmacovigilance is needed to identify and manage these cases.

31 August 2022 in The Lancet Digital Health
Verified
Journal Article
Open access
JSJan Albert Staessen
Jan Albert Staessen
RWRalph Wendt
Ralph Wendt
YYYu-Ling Yu
Yu-Ling Yu
SKSven Kalbitz
Sven Kalbitz
LTLutgarde Thijs
Lutgarde Thijs
PMPatrycja Marciniak-Stępak
Patrycja Marciniak-Stępak
The SARS-CoV-2 pandemic is a worldwide challenge. The CRIT-CoV-U pilot study generated a urinary proteomic biomarker consisting of 50 peptides (COV50), which predicted death and disease progression from SARS-CoV-2. After the interim analysis presented for the German Government, here, we aimed to analyse the full dataset to consolidate the findings and propose potential clinical applications of this biomarker. CRIT-CoV-U was a prospective multicentre cohort study. In eight European countries (Austria, France, Germany, Greece, North Macedonia, Poland, Spain, and Sweden), 1012 adults with PCR-confirmed COVID-19 were followed up for death and progression along the 8-point WHO scale. Capillary electrophoresis coupled with mass spectrometry was used for urinary proteomic profiling. Statistical methods included logistic regression and receiver operating characteristic curve analysis with a comparison of the area under curve (AUC) between nested models. Hospitalisation costs were derived from the care facility corresponding with the Markov chain probability of reaching WHO scores ranging from 3 to 8 and flat-rate hospitalisation costs adjusted for the gross per capita domestic product of each country. From June 30 to Nov 19, 2020, 228 participants were recruited, and from April 30, 2020, to April 14, 2021, 784 participants were recruited, resulting in a total of 1012 participants. The entry WHO scores were 1–3 in 445 (44%) participants, 4–5 in 529 (52%) participants, and 6 in 38 (4%) participants; and of all participants, 119 died and 271 had disease progression. The odds ratio (OR) associated with COV50 in all 1012 participants for death was 2·44 (95% CI 2·05–2·92) unadjusted and 1·67 (1·34–2·07) when adjusted for sex, age, BMI, comorbidities, and baseline WHO score; and for disease progression, the OR was 1·79 (1·60–2·01) when unadjusted and 1·63 (1·41–1·91) when adjusted (p<0·0001 for all). The predictive accuracy of the optimised COV50 thresholds was 74·4% (71·6–77·1%) for mortality (threshold 0·47) and 67·4% (64·4–70·3%) for disease progression (threshold 0·04). When adjusted for covariables and the baseline WHO score, these thresholds improved AUCs from 0·835 to 0·853 (p=0·033) for death and from 0·697 to 0·730 (p=0·0008) for progression. Of 196 participants who received ambulatory care, 194 (99%) did not reach the 0·04 threshold. The cost reductions associated with 1 day less hospitalisation per 1000 participants were million Euro (M€) 0·887 (5–95% percentile interval 0·730–1·039) in participants at a low risk (COV50 <0·04) and M€2·098 (1·839-2·365) in participants at a high risk (COV50 ≥0·04). The urinary proteomic COV50 marker might be predictive of adverse COVID-19 outcomes. Even in people with mild-to-moderate PCR-confirmed infections (WHO scores 1–4), the 0·04 COV50 threshold justifies earlier drug treatment, thereby potentially reducing the number of days in hospital and associated costs. German Federal Ministry of Health.

18 August 2009 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
IKI. Kübler
I. Kübler
MKM. J. Koslowski
M. J. Koslowski
MGM. Gersemann
M. Gersemann
KFK. Fellermann
K. Fellermann
JBJ. Beisner
J. Beisner
JWJ. Wehkamp
J. Wehkamp

15 March 2007 in Zeitschrift für Gastroenterologie
Verified
Journal Article
Closed access
CSC. Schäfer
C. Schäfer
KRKatja Rothfuss
Katja Rothfuss
HKH.-P. Kreichgauer
H.-P. Kreichgauer
ESE. F. Stange
E. F. Stange
Die Doppelballon-Enteroskopie (DBE) ermöglicht es, ein dünnes Endoskop weit in den Dünndarm vorzuschieben, sodass bisher unerreichbare Läsionen inspiziert, biopsiert und endoskopisch behandelt werden können. Diese retrospektive Analyse untersucht den diagnostischen und therapeutischen Nutzen bei allen Patienten, die sich an unserem Krankenhaus einer DBE unterzogen. Insgesamt wurden 109 DBE bei 82 Patienten durchgeführt (57 Patienten mit Verdacht auf Dünndarmblutung und 25 mit anderen Indikationen). Die diagnostische Erfolgsrate betrug 51 von 82 (62 %) Patienten, und war vor allem in der Gruppe der Bluter hoch, bei denen sich am häufigsten Angiodysplasien fanden. DBE hatte therapeutische Konsequenzen bei 47 Patienten (57 %), von denen 33 (40 %) endoskopisch und 6 (7 %) chirurgisch behandelt wurden. Bei vier Patienten wurden Malignome neu festgestellt (2 gastrointestinale Stromatumoren, 1 neuroendokriner Tumor, 1 Adenokarzinom). Andere diagnostische Modalitäten erwiesen sich bei der Indikationsstellung und der Wahl des Zugangswegs (oral oder anal) als hilfreich. Bei 16 von 26 Patienten mit pathologischen Videokapsel-Befunden fand sich ein Korrelat in der DBE. Bei 7 Patienten wurden die Befunde einer CT- oder MR-Sellink-Untersuchung, und bei 4 Patienten mit Hämatochezie die Befunde eines Erythrozytenszintigramms bestätigt. Diese Daten zeigen, dass die DBE des Dünndarms - im Kontext mit anderen diagnostischen Modalitäten - eine hohe diagnostische und therapeutische Effektivität besitzt. Double-balloon enteroscopy (DBE) is a newly developed method allowing deep insertion of a thin endoscope into the small bowel, thereby enabling inspection, biopsy and endoscopic treatment of previously inaccessible lesions. This retrospective analysis evaluates the diagnostic and therapeutic efficacy in all patients undergoing DBE at our institution. A total of 109 DBEs were performed in 82 patients (57 patients with suspected small bowel blood loss and 25 patients with other indications). The diagnostic success rate was 51 of 82 (62 %) with a higher rate in bleeders in whom angiodysplasias were the most frequent diagnosis. DBE had therapeutic consequences in 47 patients (57 %), of whom 33 patients (40 %) underwent endoscopic therapy and 6 patients (7 %) surgery. In 4 patients, malignant neoplasias were newly diagnosed (2 gastrointestinal stroma tumors, 1 neuroendocrine tumor, 1 adenocarcinoma). Other diagnostic modalities were helpful in preselecting patients for DBE and choosing the more favorable (oral or anal) access. In 16 of 26 patients, pathological findings in videocapsule endoscopy were substantiated by DBE. In 7 patients, the findings of CT or MRI enteroclysis, and in 4 patients with hematochezia, the results of a preceding erythrocyte bleeding scan were confirmed by DBE. In conclusion, this series indicates that DBE of the small bowel - in concert with other diagnostic modalities - has a high diagnostic and therapeutic efficacy.

8 October 2021 in Infection
Verified
Journal Article
Open access
PDF file
MSMaximilian J. Schons
Maximilian J. Schons
ACAmke Caliebe
Amke Caliebe
CSChristoph Spinner
Christoph Spinner
ACAnnika Y. Classen
Annika Y. Classen
LPLisa Pilgram
Lisa Pilgram
TGthe LEOSS-study group
the LEOSS-study group
Purpose Reported antibiotic use in coronavirus disease 2019 (COVID-19) is far higher than the actual rate of reported bacterial co- and superinfection. A better understanding of antibiotic therapy in COVID-19 is necessary. Methods 6457 SARS-CoV-2-infected cases, documented from March 18, 2020, until February 16, 2021, in the LEOSS cohort were analyzed. As primary endpoint, the correlation between any antibiotic treatment and all-cause mortality/progression to the next more advanced phase of disease was calculated for adult patients in the complicated phase of disease and procalcitonin (PCT) ≤ 0.5 ng/ml. The analysis took the confounders gender, age, and comorbidities into account. Results Three thousand, six hundred twenty-seven cases matched all inclusion criteria for analyses. For the primary endpoint, antibiotic treatment was not correlated with lower all-cause mortality or progression to the next more advanced (critical) phase (n = 996) (both p > 0.05). For the secondary endpoints, patients in the uncomplicated phase (n = 1195), regardless of PCT level, had no lower all-cause mortality and did not progress less to the next more advanced (complicated) phase when treated with antibiotics (p > 0.05). Patients in the complicated phase with PCT > 0.5 ng/ml and antibiotic treatment (n = 286) had a significantly increased all-cause mortality (p = 0.029) but no significantly different probability of progression to the critical phase (p > 0.05). Conclusion In this cohort, antibiotics in SARS-CoV-2-infected patients were not associated with positive effects on all-cause mortality or disease progression. Additional studies are needed. Advice of local antibiotic stewardship- (ABS-) teams and local educational campaigns should be sought to improve rational antibiotic use in COVID-19 patients.